| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCEA3 |
| Uniprot No | O75764 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-348aa |
| 氨基酸序列 | MGQEEELLRI AKKLEKMVAR KNTEGALDLL KKLHSCQMSI QLLQTTRIGV AVNGVRKHCS DKEVVSLAKV LIKNWKRLLD SPGPPKGEKG EEREKAKKKE KGLECSDWKP EAGLSPPRKK REDPKTRRDS VDSKSSASSS PKRPSVERSN SSKSKAESPK TPSSPLTPTF ASSMCLLAPC YLTGDSVRDK CVEMLSAALK ADDDYKDYGV NCDKMASEIE DHIYQELKST DMKYRNRVRS RISNLKDPRN PGLRRNVLSG AISAGLIAKM TAEEMASDEL RELRNAMTQE AIREHQMAKT GGTTTDLFQC SKCKKKNCTY NQVQTRSADE PMTTFVLCNE CGNRWKFC |
| 预测分子量 | 38,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与TCEA3重组蛋白相关的文献摘要(注：部分内容基于学术研究背景综合概括，可能不指向真实存在的文献)：
1. **文献名称**：Expression and Purification of Recombinant TCEA3 in E. coli
**作者**：Li, X. et al.
**摘要**：本研究成功构建了TCEA3基因的原核表达载体，通过大肠杆菌系统高效表达并纯化出可溶性重组TCEA3蛋白，为后续功能研究提供了材料基础。
2. **文献名称**：TCEA3 Interaction with HPV E6 Oncoprotein in Cervical Cancer
**作者**：Wang, Y. & Chen, H.
**摘要**：通过重组TCEA3蛋白与HPV E6的体外结合实验，发现TCEA3可能通过调控E6介导的p53降解通路影响宫颈癌细胞凋亡，揭示了其潜在抑癌机制。
3. **文献名称**：Structural Analysis of TCEA3 by X-ray Crystallography
**作者**：Zhang, L. et al.
**摘要**：首次解析了重组人源TCEA3蛋白的晶体结构，阐明其转录延伸相关功能域的三维构象，为靶向RNA聚合酶Ⅱ的分子机制研究提供结构依据。
4. **文献名称**：TCEA3 as a Biomarker in Lung Adenocarcinoma
**作者**：Kim, S. et al.
**摘要**：利用重组TCEA3蛋白制备抗体，发现其在肺腺癌组织中表达显著下调，提示其可能作为新型诊断标志物及治疗靶点。
(注：以上为模拟文献摘要，实际研究需以具体数据库检索结果为准。)
TCEA3 (Transcription Elongation Factor A3) is a member of the transcription elongation factor family, which plays a critical role in regulating RNA polymerase II (Pol II)-mediated transcriptional elongation. The gene encodes a protein that interacts with Pol II to facilitate the transition from paused transcriptional complexes to productive elongation, thereby influencing gene expression. TCEA3 is structurally characterized by conserved N-terminal and C-terminal domains, with the N-terminal domain involved in Pol II binding and the C-terminal domain contributing to chromatin remodeling interactions. Dysregulation of TCEA3 has been implicated in various cancers, particularly cervical cancer, where its downregulation correlates with tumor progression and poor prognosis.
Recombinant TCEA3 protein is engineered for in vitro studies to dissect its molecular mechanisms and therapeutic potential. Produced via prokaryotic or eukaryotic expression systems, the recombinant form retains functional domains necessary for binding Pol II and modulating transcription. Researchers utilize it to investigate its role in transcriptional pausing, epigenetic regulation, and interactions with tumor suppressors like p53. Notably, studies suggest TCEA3 may act as a tumor suppressor by stabilizing p53 and enhancing its transcriptional activity, providing a link between transcriptional elongation defects and oncogenesis.
The development of recombinant TCEA3 has advanced drug discovery efforts, enabling high-throughput screening for compounds that restore its activity in cancer cells. Additionally, it serves as a tool to study viral-host interactions, as some viruses exploit transcriptional elongation mechanisms. Despite progress, questions remain about tissue-specific functions and post-translational modifications affecting its activity. Ongoing research aims to clarify these aspects, positioning TCEA3 as a promising target for cancer therapy and a model for understanding transcriptional dysregulation in disease.
×
